Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
660
Trial Sponsor
Clinical Trial Start Date
April 7, 2017
0Primary Completion Date
July 1, 2017
0Study Completion Date
May 6, 2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
VXA-G1.1-NN Oral Vaccine0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers0
Last Updated
May 30, 2018
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
A Phase 1b, randomized, double-blind, dose-ranging trial to determine the safety of different dosing regimens an adenoviral-vector based norovirus vaccine (VXA-G1.1-NN) expressing GI.1 VP1 and dsRNA adjuvant administered orally to healthy volunteers
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
